다기관 전향적 임상연구를 위한 웹 데이터베이스 시스템

김혜림,최신영,유은미,박지숙 서울여자대학교 2010 정보기술논문지 Vol.8 No.-

Because many centers jointly select the subject, multi-center clinical study can promptly recruit various patient groups into the research, thus being advantageous in terms of generalization. However, prospective clinical study has difficulties in implementation, because it takes a lot of efforts to trace a large scale of subjects. The purpose of this study is to develop a web database system suitable for multi-center prospective clinical study. This study has presented three basic strategies-accurate data input, easy data tracing, and real-time data verification-to supplement the demerits of prospective clinical study. The developed system has been applied in the clinical study proceeded by the study group for Respiratory failure which is affiliated to The Korean Academy of Tuberculosis and Respiratory Diseases's Association for Research on Respiratory Failure and has been verified of its performance.

알루미늄 압출부재의 굽힘붕괴 특성식 산출에 관한 연구

강신유,장혜정 강원대학교 산업기술연구소 2000 産業技術硏究 Vol.20 No.B

In this paper, we would like to develop the bending collapse specific equation of aluminum members which are usually used in light-weight vehicle or electromobiles. The result of the developed equation are compared with that of test and finite element methods as the moment-rotational angle curves. Three types of aluminum members are tested with the pure bending collapse test rig. PAM-CRASH and ABAQUS program are used for finite element analysis. As the result the developed bending collapse governing equation is accurate in estimating the yield moment and the maximum moment. Especially, in the case of the local buckling and the delayed buckling, the developed equation is better effective than F.E.M.

2-구획 인공 모세혈관 모델을 이용한 Pseudomonas aeruginosa 임상균주에 대한 Panipenem의 효과

이동건,전혜선,최수미,최정현,유진홍,신완식 대한감염학회 2004 감염과 화학요법 Vol.36 No.4

목적 : Panipenem은 일본에서 개발된 카바페넴계 항생제로 광범위한 항균력을 나타낸다고 보고되고 있지만 P. aeruginosa에 대해서는 아직 논란이 있다. 본 연구에서는 임상에서 분리된 P. aeruginosa 균주를 대상으로 사람의 약역학을 모의할 수 있는 시험관내 역동 모델을 이용하여 panipenem (PAPM)과 imipenem (IMPM)의 효과를 비교하고 Muller-Hinton broth (MHB)와 basic amino acid 함량이 적은 배지(Minimum Broth Davis, MBD)에 효과의 차이가 있는지 확인하고자 하였다. 재료 및 방법 : 혈액에서 분리된 P. aeruginosa SGP14 균주를 대상으로 하였다. 사람의 약동학을 모의할 수 있는 2-구획 인공 모세혈관 모델(two-compartment model)을 제작하였고, 세균이 peripheral compartment에서 반감기에 따라 농도가 변하고 있는 항생제에 노출되고, 접종한 세균의 수는 희석되지 않게 하였다. PAPM과 IMPM의 용량은 500mg씩 하루 2회를 모의하도록 하였고 2일간 실험하였다. Panipenem, imipenem의 반감기는 사람의 약역학과 같이 10시간에 맞추었다. 항생제 투여 간격은 panipenem, imipenem 모두 12시간으로 하였고 각 항생제의 최고 및 최저농도는 사람에 투여했을 때의 혈중농도에 맞추었다(panipenem 각각 45.6, 0 ug/mL, imipenem 각각 33.0, 0 ug/mL). 배지는 MHB와 MBD를 사용하였고 4군으로 나누어 실험하였다. [PAPM (MHB), PAPM (MBD), IMPM (MHB), IMPM (MBD)] peripheral compartment에서 0, 1, 2, 4, 6, 8, 12, 24, 32, 48시간에 맞춰 샘플을 하였고 집락수 (cfu/mL)를 측정하였다. 결과 : SGP14에 대한 PMPM, IMPM의 MIC는 각각 64, 2 ug/mL이었다. PAPM (MHB)는 2시간이 지나면서 다시 자라기 시작하여 32시간째부터는 항생제를 사용하지 않은 대조군과 같은 곡선을 보였다. 12시간까지의 집락수 변화는 4가지 실험군에서 군간 의미있는 차이를 보이지 않았지만(P=0073) 군내의 PAPM (MHB)가 PAPM(MBD), IMPM (MBD)와 비교하여 집락수 변화가 유의하게 작았다. 또한 48시간까지의 집락수 변화는 PAPM(MBD)이 가장 많았고, 그 다음이 IMPM (MHB), IMPM(MBD)였으며, PAPM(MHB) 순이었다(P=000). 48시간까지 집락수 변화는 IMPM (MHB)와 IMPM (MBD)사이에 차이가 없었다. 결론 : 사람의 혈청내 basic amino acid 농도와 PAPM의 농도를 모의하도록 한 2-구획 인공 모세혈관 모델에서 PAPM은 IMPM과 비교하여 P. aeruginosa에 대해 비슷하거나(12시간째) 더 나은 살균력을 보였다(48시간째). 추후 본 실험의 결과와 실제 임상에서의 P. aeruginosa에 대한 panipenem의 효과를 비교해보는 것이 필요하겠다. Background : Panipenem (PAPM) is a new carbapenem which has an enhanced broad spectrum activity against both gram-positive and negative organisms. However, its activities in vitro against Pseudomonas aeruginosa are still under controversy. The aim of this study was to compare the activity of PAPM with those of imipenem (IMPM) against clinical isolates of P. aeruginosa using in vitro kinetic model and to evaluate the differences according to the quantity of basic amino acid in media. Materials and methods : Using a clinical isolate of P. aeruginosa (SGP14) from blood, an in vitro 2-compartment artificial capillary model based on a dialyzer unit was prepared. Antibiotics were given as a bolus q12 hrs for 48 hrs. Simulated doses and frequencies of PAPM and IMPM were 500 mg q12 hrs as approved by Korea Food and Drug Administration. Muller-Hinton broth (MHB) and minimal broth Davis (MBD) were used as culture media and we divided the experiments into 4 groups [PAPM (MHB), PAPM (MBD), IMPM (MHB), IMPM (MBD)]. At 0, 1, 2, 4, 6, 8, 12, 24, 32, and 48 h, samples were removed from peripheral compartment and viable bacterial counts were measured. Results : The susceptibility of PAPM and IMPM for SGP14 were 64 and 2 ug/mL in MHB and 4 and 2 ug/mL in MBD, respectively. Up until 12 hours, changes in bacterial colony counts were not significantly different (P=0.073) for each group. However among the four groups, PAPM (MHB) showed the least changes compared with PMPM (MBD), IMPM (MBD). The largest decrement of colony during 48 hours was observed with PMPM (MBD), followed by IMPM (MHB) or IMPM (MBD), and PAPM (MHB) in decreasing order (P=0.00). There were no differences between IMPM (MHB) and IMPM (MBD) as for the change in colony counts. Conclusions : The bactericidal activities of panipenem against the clinical isolate of P. aeruginosa was similar (at 12 h) or superior (at 48 h) to that of imipenem in an in vitro 2-compartment artificial capillary model using minimal broth to simulate human serum drug concentrations.

알부민이 첨가된 시험관내 약역학 감염모델을 이용한 폐렴알균 치료에서 Ceftriaxone 일일 1회 요법

허지안,전혜선,박선희,최수미,김시현,이동건,최정현,유진홍,신완식 대한감염학회 2006 감염과 화학요법 Vol.38 No.6

배경 : Penicillin 내성 폐렴알균이 증가하는 지역에서 대안 중의 하나로 사용되는 ceftriaxone (CTR)의 적절한 용법, 용량을 파악하는 것이 중요하다. 본 연구는 임상에서 분리된 폐렴알균을 대상으로 시험관내 약역학 감염모델을 이용하여 알부민이 첨가된 경우와 첨가되지 않은 경우 CTR의 일일 1회 요법의 효과를 비교해 보고자 하였다. 재료 및 방법 : Penicillin 감수성(SM24), 중간내성(SM47), 내성(SM60)주를 대상으로 2-구획 시험관내 약역학 감염모델을 적용하였다. CTR 주입은 2 g씩 24시간마다로 사람의 약동학을 모의하였다. 알부민은 모델에서 4g/ dL가 유지되도록 하였다. 살균효과는 0, 2, 4, 6, 24, 30, 48시간째 집락수 변화로 측정하였다. 결과 : 모든 균주에서 알부민이 첨가되지 않은 경우 6시간 이내에 살균력이 관찰되었다. 최저억제농도 및 알부민 첨가유무에 관계없이 3주 모두 24시간째 살균력이 관찰되었고, 48시간째는 모두 측정한계 이하의 집락수로 감소하였다. 전 실험과정에서 CTR에 대한 내성주는 출현하지 않았다. 결론 : CTR의 일일 1회 요법은 알부민이 첨가되었을 때, 감수성, 중간내성, 내성주 모두에서 살균력 발현이 지연되었으나 최종효과는 알부민이 없을 때와 다르지 않았다. 앞으로 알부민 결합효과와 관련된 기초적인 추가 연구가 필요할 것으로 생각된다. Background : During the era of increasing penicillin resistant Streptococcus pneumoniae, it is important to have knowledge about adequate dosage and dosing interval of ceftriaxone (CTR). We examined efficacies of once-daily CTR and compared results in an in vitro pharmacodynamic infection model (IVPDIM) supplemented with albumin and those without albumin. Methods : Using three clinically isolated S. pneumoniae that were susceptible (SM24), intermediate (SM47) and resistant (SM60) against CTR, we utilized a two-compartment IVPDIM. CTR 2 g was administered intravenously every 24 h. Human albumin was added with concentration of 4 g/dL. Samples were removed at multiple time points over a 48-h period to determine the colony counts. Results : In SM24 and SM60, bactericidal effects were observed within 6 hours in groups without albumin. The number of colonies during 1st 6 hours were more decreased in albumin-free groups than in albumin-supplemented groups (P<0.05). In SM47, similar results were found during 1st 6 hours (P=0.03). But, regrowth was observed in albumin supplemented group at 30 h. Irrespective of results of minimal inhibitory concentrations and albumin supplementation, bactericidal effects were shown at 24 h in all 3 strains. All groups were decreased below the detection limit at 48 h. Development of resistance was not detected throughout the entire study period in either strain. Conclusions : Although extents of killing in albumin supplemented broth of once-daily CTR dosing were delayed in all 3 strains compared with those of albumin free broth, final efficacies were not different between the two groups.

시험관내 심내막염 모델에서 Methicillin 내성 포도구균에 대한 Vancomycin, Arbekacin, Gentamicin 단독 혹은 병합효과

이동건,전혜선,임동석,최수미,최정현,유진홍,신완식,강문원 대한감염학회 2003 감염과 화학요법 Vol.35 No.3

목적 : Methicillin 내성 포도구균(methicillin resistant Staphylococcus aureus, MRSA)은 병원감염의 중요한 원인균으로 vancomycin이 선택약제이다. 그러나 심내막염 등의 중증감염에서는 vancomycin의 치료실패와 함께 최근 내성균도 증가하고 있어 vancomycin을 대체할 수 있는 항균제와 보다 효과적인 항균요법의 개발이 필요하다. 본 연구에서는 사람의 환경과 유사한 시험관내 감염 모델을 적용하여 MRSA 치료를 위한 vancomycin, arbekacin, gentamicin의 단독 및 병합효과를 비교하였다. 방법 : 임상에서 분리된 MRSA 2균주(GRI 53, gentamicin 내성 : GS171, gentamicin 감수성)로 fibrin clot을 제작하여 시험관내 심내막염 모델을 만들어 vancomycin, arbekacin, gentamicin을 단독 혹은 병합주입하였다. 반감기와 최고 및 최저농도는 사람의 약동학을 기준으로 하였다. Vancomycin은 6, 12, 24시간마다 주입하거나 24시간 연속주입하였고 arbekacin은 12, 24시간마다, gentamicin은 8, 24시간마다 주입하였다. 병합주입의 경우 vancomycin은 12시간마다, gentamicin, arbekacin은 24시간마다 투여하였다. 각 투여군의 살균효과는 0, 8, 24, 32, 48, 72시간째의 fibrin clot내 집락수로 측정하였다. 결과 : GRI153에 gentamicin을 주입한 군 이외의 모든 실험군에서 대조군에 비해 의미있게 fibrin clot내 집락수가 감소하였다(P<0.001). Vancomycin과 arbekacin 단독주입군내서 8시간째의 집락수는 GRI153보다 GS171에서 의미있게 낮았고(P=0.02), GS171에 arbekacin 12시간마다 투여한 군의 집락수가 가장 낮았다(P=0.01). 72시간째 집락수는 균주의 종류나 vancomycin 혹은 arbekacin의 투여간격에 따른 차이가 없었다. GRI153에서 vancomycin과 arbekacin의 병합주입군은 24시간까지 상가작용이 있었으나 vancomycin과 gentamicin 병합주입에서는 무관작용이었고 GS171에서도 72시간 동안 무관작용을 보였다. 또한 전 실험기간 동안 내성균은 발현되지 않았다. 결론 : 시험관내 심내막염 모델에서 MRSA에 대한 arbekacin의 항균력은 vancomycin과 유사하여 단독주입이 가능함을 시사한다. Gentamicin 내성균주의 경우 두가지 항균제의 병합주입으로 24시간까지 상가작용을 보이고 있으나 임상에 적용하기 위해서는 추가연구가 필요할 것으로 생각된다. Background : Glycopeptide has been used for the one-and-only treatment of choice in methicillin resistant Staphylococcus aureus (MRSA) infection, but its exclusive use for the MRSA infection has led to the increased risk of glycopeptide-resistance. To find an alternative (s), we employed an in vitro infective endocarditis model (IVIEM) to compare the efficacy of vancomycin (VCM). arbekacin (ABK), and gentamicin (GM) alone or in combination. Methods : Using two strains of clinically isolated MRSA, one GM susceptible (GS171) and the other GM resistant (GR153), fibrin clots were prepared and suspended in IVIEM. Antibiotics were added as a bolus to simulate human pharmacokinetics of regimens, including q 6 h, q 12 h, q 24 h, or continuous infusion with VCM, q 12h or q 24 h with ABK, and q 8 h or q 24 h with GM. In cases of combination, regimens were VCM q 12 h plus ABK q 24 h, and VCM q 12 h plus GM q 24 h. Fibrin clots were removed from each model at 0, 8, 24, 32, 48. and 72 h, and the bacterial densities (in CFU/g) were determined. Results : At 8 hour, the colony counts of GS171 were lower than those of GR153 (P=0.02), and the lowest with the ABK q12h against GS171 (P=0.01). At 72 hour, monotherapy with ABK or VCM produced same degree of bacterial reductions in IVIEM, regardless of dosing frequency or GM-resistance. In the case of GM-resistance, combination of VCM and ABK did show additive effect until 24 hours, although VCM and GM showed no indifference during all the experiments. Development of resistance during experiment was not observed with any regimens. Conclusions : Our data suggest that ABK monotherapy could be used as an alternative to VCM even in the treatment of GM-resistant staphylococcal endocarditis. Further studies will clinical trials are warranted to evaluate the additive effect of VCM and ABK.

임부의 연령에 따른 보완대체요법에 관한 인식 태도 경험 비교 연구

김연진,김지연,노경민,신혜리,유예지,이지민,장희조,정아인,최소정,강숙정,이향연,민혜영 이화여자대학교 간호과학대학 2016 이화간호학회지 Vol.- No.50

Purpose: This study aims to test if the age of pregnant women affects the perception, experience, and attitude towards complementary alternative therapy (CAT), by investigating the perception, experience, and attitude of pregnant women under the age of 35, and above 35 (Advanced Maternal Age). The study will 1) find the general characteristics of pregnant women under and over the age of 35 2) compare the perception, behavior, and experience of pregnant women under and over the age of 35, and 3) find the comparison of the perception, behavior, and experience according to the general characteristics of pregnant women under and over the age of 35. Method: The subjects of this study are composed of 44 women under the age of 35 and 44 women above the age of 35, totaling 88 pregnant women visiting midwiferies, obstetrics and gynecology, and baby fairs in Seoul and Gyeong-Gi area. Data for this study was collected from November 28, 2015 to January 6, 2016 for 40 days. The collected data analyzed mean, standard deviation, t test, ANOVA, and chi-square by using SPSS 23.0. Result Results show that there is a significant difference in the perception, attitude, and experience of the two-sample groups in the use of CAT. The question of “what is most necessary when applying CAT in a hospital clinical environment” for the perception criteria came out with the results of t=9.980, p<.05. For the attitude, results showed that the answers of pregnant women under the age of 35 displayed a more positive attitude towards CAT. (t=2.421, p<.05) Lastly, in the experience section, pregnant women under the age of 35 showed more CAT use than the other sample group. Conclusion Results have shown that there is a difference in the perception, behavior, and experience between the two sample groups. Therefore further research on the efficacy and the adverse effects of CAT needs to be done.

Panipenem을 포함한 Carbapenem 계열 항생제의 몇 가지 임상균주에 대한 시험관내 항균력

이동건,김명신,강진한,전혜선,최수미,위성헌,김상일,최정현,유진홍,신완식,강문원 대한감염학회 2003 감염과 화학요법 Vol.35 No.2

목적 : Panipenem은 일본에서 개발된 카바페넴계 항생제로 그람양성균, 그람음성균, 혐기균에 이르기까지 광범위한 항균력을 나타낸다고 보고되고 있지만 국내에서 분리되는 균주에 대한 감수성 검사결과는 아직 없다. 본 연구에서는 임상에서 분리된 E. coli, K. pneumoniae, P. aeruginosa, S. pneumoniae 균주를 대상으로 carbapenem 계열 및 몇 가지 항생제와 감수성을 비교하고, 특히 P. aeruginosa의 경우 carbapenem의 효과를 Muller-Hinton agar (MHA)가 반감시킬 수 있는 특성을 고려하여 감수성에 변화가 있는지 확인하고자 하였다. 방법 : 2002년 3월부터 6월까지 가톨릭대학교 성모병원, 강남성모병원, 성가병원, 성모자애병원, 성빈센트병원에서 분리된 임상균주 E. coli, K. pneumoniae, P. aeruginosa, S. pneumoniae를 대상으로 하였다. 항생제 감수성 검사는 NCCLS 기준에 따랐고 P. aeruginosa의 경우 MHA 이외에 minimal agar Davis (MAD)를 추가로 사용하였다. 감수성 결과 해석시 panipenem은 imipenem과 같은 기준을 적용하였다. 결과 : E. coli, K. pneumoniae, P. aeruginosa는 각각 100균주였고, S. penumoniae는 134균주였다(PSSP 41, PNSP 93균주). E. coli, K. pneumoniae는 모든 균주가 imipenem, meropenem, panipenem에 대해 감수성을 보였다. P. aeruginosa의 경우 imipenem, meropenem, panipenem, ceftazidime의 MIC_(90)은 각각 16, 8, 32, 64㎍/mL이었다. MHA와 MAD 배지를 이용하여 P. aeruginosa에 대한 항생제 감수성을 비교해 본 결과 imipenem, panipenem의 MIC_(90)가 각각 16, 32㎍/mL에서 8㎍/mL로 감소하였고, imipenem에 비해 panipenem이 더 많이 감소하였다. S. pneumoniae의 경우 PSSP는 imipenem, meropenem, panipenem에 대해 모두 내성이 없었고 PNSP는 imipenem, meropenem, panipenem에 대한 MIC_(90)가 각각 1, 2, 0.25㎍/mL이었다. 결론 : 결론적으로 panipenem은 E. coli, K. pneumoniae에 대해 기존의 카바페넴계 항생제와 유사한 우수한 항균력을 보였다. P. aeruginosa의 경우 ceftazidime, imipenem과 비슷한 항균력을 보였고 아미노산 함량이 적은 배지를 사용함에 따라 MIC가 낮아졌으며 imipenem보다 더 많은 영향을 받았다. S. pneumoniae의 경우 특히 PNSP에서 기존의 카바페넴계 항생제보다 우수한 항균력을 보였다. Panipenem은 주요 그람음성균 및 폐렴연쇄구균 감염에 유용할 것으로 기대된다. Background : Panipenern (PAPM) is a new carbapenern which has an enhanced broad spectrum against both gram-positive and negative organisms. The aim of study was to compare the activities of PAPM with those of imipenern (IMPM), meropenern (MRPM) against several clinical isolates in Korea. Methods : We tested the in vitro antimicrobial activities of PAPM, IMPM, and MRPM against total 300 clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa and 134 Streptococcus pneumoniae collected from 5 different university hospitals. Using NCCLS guidelines, MICs of PAPM, IMPM, MRPM, and/or ceftazidime were determined. Results : All isolates of E. coli and K. pneumoniae were susceptible to PAPM, IMPM and MRPM. MIG_(90) of PAPM, IMPM, and MRPM against P. aeruginosa were 32, 16, and 8 ㎍/mL, respectively. Comparing Mueller-Hinton agar (MHA) and minimal agar Davis (MAD), the MIG_(go) of PAPM and IMPM were reduced from 16 and 32 ㎍/mL to 8 and 8 ㎍/mL, respectively. PAPM was more influenced by MAD than IMPM. All isolates of penicillin susceptible S. pneumoniae showed 0% of resistance to the carbapenems tested. MIC_(90) of PAPM, IMPM and PRPM against penicillin non-susceptible S. pneumoniae were 0.25, 1 and 2 ㎍/mL, respectively. Conclusion : Panipenern could be one of the potentially useful drugs for the treatment of infections caused by E. coli, K. pneumoniae, and S. pneumoniae. We also showed that PAPM had good anti-pseudomonal activity when examined in MAD, the amino acid-limited media. Therefore, it could be useful for the treatment of infections caused by P. aeruginosa.

The impact of COVID-19 on cancer care in a tertiary hospital in Korea: possible collateral damage to emergency care

Yoo Shin Hye,Sim Jin-Ah,Shin Jeongmi,김범석,Park Jun-Bean,Shin Aesun 한국역학회 2022 Epidemiology and Health Vol.44 No.-

OBJECTIVES: We investigated the impact of the COVID-19 pandemic on cancer care in a tertiary hospital in Korea without specific lockdown measures.METHODS: A retrospective cohort of cancer patients from one of the largest tertiary hospitals in Korea was used to compare healthcare utilization in different settings (outpatient cancer clinic, the emergency department [ED], and admissions to the hematology/oncology ward) between January 1 and December 31, 2020 and the same time period in 2019. The percent changes in healthcare utilization between the 2 periods were calculated.RESULTS: A total of 448,833 cases from the outpatient cohort, 26,781 cases from the ED cohort, and 14,513 cases from the admission cohort were reviewed for 2019 and 2020. The total number of ED visit cases significantly decreased from 2019 to 2020 by 18.04%, whereas the proportion of cancer patients remained stable. The reduction in ED visits was more prominent in patients with symptoms suspicious for COVID-19, high-acuity cases, and those who lived in non-capital city areas. There were no significant changes in the number of total visits, new cases in the outpatient clinic, or the total number of hospitalizations between the 2 periods.CONCLUSIONS: During the pandemic, the number of ED visits significantly decreased, while the use of the outpatient clinic and hospitalizations were not affected. Cancer patients’ ED visits decreased after the COVID-19 outbreak, suggesting the potential for collateral damage outside the hospital if patients cannot reach the ED in a timely manner.

Successful Treatment of Chronic Eosinophilic Pneumonia with Anti-IgE Therapy

Shin, Yoo Seob,Jin, Hyun Jung,Yoo, Hye-Soo,Hwang, Eui-kyung,Nam, Young Hee,Ye, Young-Min,Park, Hae-Sim The Korean Academy of Medical Sciences 2012 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.27 No.10

<P>Anti-IgE therapy, using recombinant humanized anti-IgE antibodies, is clinically effective in patients with eosinophil-related disorders such as allergic asthma, allergic rhinitis, and chronic urticaria. Chronic eosinophilic pneumonia tends to respond promptly to systemic corticosteroid therapy, however; relapses are common following corticosteroid tapering. We treated two patients (17- and 19-yr-old males) of chronic eosinophilic pneumonia whose symptoms were cough and dyspnea on exertion. The symptoms were recurrent while tapering off corticosteroid. They were treated with anti-IgE antibody without recurrence for 2 yr and 15 months. Here, we first describe clinical experience of the 2 cases of chronic eosinophilic pneumonia.</P>

Enantioselective carbonyl reduction of eperisone in human liver microsomes

Yoo, Hye Hyun,Kim, Nam-Sun.,Kim, Min Jung,Shin, Dongyun,Shin, Jae-Gook,Kim, Dong-Hyun Informa Healthcare 2011 Xenobiotica Vol.41 No.9

<OL><LI><P>Eperisone, 4-ethyl-2-methyl-3-piperidinopropiophenone, is a centrally acting muscle relaxant widely used to relieve muscle stiffness and back pain. In this study, enantioselectivity for carbonyl reduction of eperisone was investigated in human liver microsomes, and the enzymes involved in the carbonyl reduction were characterised.</P></LI><LI><P>Carbonyl reduction of eperisone predominantly occurred in microsomal fractions and 11β棺-hydroxysteroid dehydrogenase type 1(11β棺-HSD 1) played a major role in this reaction as judged by selective inhibition of the activity by BVT-14225 and KR-66344. The kinetic study with (++)-S- and (−??)-R-eperisone showed that the formation of the carbonyl reduced metabolite (M5) from the (−??)-R-isomer was more efficient than that from the (−??)-S-isomer.</P></LI><LI><P>As eperisone is a racemic compound with one chiral centre, the carbonyl reduced metabolite of eperisone (M5) may have four possible diastereoisomeric structures. Chiral separation of incubation mixtures of racemic eperisone with human liver microsome revealed that (1S, 2S)-M5 and (1R, 2R)-M5 were generated specifically from (++)-S- and (−??)-R-eperisone, respectively. Selective formation of anti-diastereomers was further confirmed by incubation of individual enantiomer with microsomes.</P></LI><LI><P>Carbonyl reduction of eperisone by microsomal 11β棺-HSD 1 may significantly contribute to the metabolic disposition of eperisone in human and (−??)-R-isomer is preferentially reduced by this enzyme.</P></LI></OL>